AI Stock Analysis - Heron Therapeutics (HRTX)
Analysis generated April 14, 2026.
Heron Therapeutics is a biotechnology company that specializes in developing treatments for disease areas such as pain management and oncology care. Known for innovative therapeutic solutions, the company aims to improve patient outcomes significantly.
Stock Alerts - Heron Therapeutics (HRTX)
 |
Heron Therapeutics | May 11 Price is down by -11.6% in the last 24h. |
|
Heron Therapeutics | May 7 Price is down by -6.1% in the last 24h. |
|
Heron Therapeutics | May 6 Price is up by 6.1% in the last 24h. |
|
Heron Therapeutics | April 27 Price is up by 6.3% in the last 24h. |
Download our app on iOS or Android to get future alerts delivered in real-time.
Alternative Data for Heron Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 12 | Sign up | Sign up | Sign up |
| Sentiment | 50 | Sign up | Sign up | Sign up |
| Webpage traffic | 5,000 | Sign up | Sign up | Sign up |
| Employee Rating | 64 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 164 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,347 | Sign up | Sign up | Sign up |
| X Mentions | 22 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $17,000 | Sign up | Sign up | Sign up |
| Business Outlook | 32 | Sign up | Sign up | Sign up |
| Linkedin Employees | 188 | Sign up | Sign up | Sign up |
About Heron Therapeutics
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care.
| Price | $0.91 |
| Target Price | Sign up |
| Volume | 2,364,928 |
| Market Cap | $181M |
| Year Range | $0.75 - $1.49 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Heron Therapeutics Q1 Earnings Call HighlightsMay 11 - Yahoo Entertainment |
|
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026April 27 - GlobeNewswire |
|
 |
Earnings Scheduled For February 26, 2026February 25 - Benzinga |
Prefilled Syringe Fill Finish Manufacturing Market, 2035: Industry Trends and Global Forecasts by Therapeutic Area, Syringe Barrel Material, Number of Barrel Chambers, Drug MoleculeFebruary 25 - GlobeNewswire |
|
Heron: Near The Bottom Of A Trading Range Despite PositivesFebruary 17 - SeekingAlpha |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '25 | 41M | 7.6M | 33M | -3M | -790,000 | -0.020 |
| Q3 '25 | 38M | 15M | 23M | -17M | -14M | -0.100 |
| Q2 '25 | 37M | 9.9M | 27M | -2.4M | -1M | -0.020 |
| Q1 '25 | 39M | 8.5M | 30M | 2.6M | 3.7M | 0.013 |
| Q4 '24 | 41M | 10M | 31M | 3.7M | 8.7M | 0.020 |
Insider Transactions View All
| Rubric Capital Management LP filed to buy 94,610 shares at $15. August 12 '25 |
| Morgan Adam filed to buy 70,012 shares at $15. August 12 '25 |
| Rubric Capital Management LP filed to buy 29,100,728 shares at $1.5. August 12 '25 |
| Morgan Adam filed to buy 8,753,290 shares at $1.5. August 12 '25 |
Similar companies
Read more about Heron Therapeutics (HRTX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
FAQ - Heron Therapeutics
The Market Cap of Heron Therapeutics is $181M.
Currently, the price of one share of Heron Therapeutics stock is $0.91.
The HRTX stock price chart above provides a comprehensive visual representation of Heron Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Heron Therapeutics shares. Our platform offers an up-to-date HRTX stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Heron Therapeutics (HRTX) does not offer dividends to its shareholders. Investors interested in Heron Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Heron Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
